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LETTERS TO THE EDITOR 
Elevated transpulmonary gradient and cardiac 
magnetic resonance-derived right ventricular 
remodeling predict poor outcomes in sickle cell 
disease 
Recent controversies regarding the prevalence of pul­
monary hypertension (PH) in patients with sickle cell dis­
ease (SCD) have been raised.' While the prevalence of PH 
differed among several SCD cohorts,2"4 the reported range 
of 6-11 % is higher than the general population and those 
with HN or scleroderma. 1 PH in SCD is often complicat­
ed by concurrent left ventricular (LV) diastolic dysfunc­
tion and anemia-related changes in hemodynamics. The 
change in pressure across the pulmonary circulation as 
reflected by the transpulmonary pressure gradient (TPG) 
can be measured during right heart catheterization 
(RHC). TPG is less clouded by anemia-related adapta-
Table 1. Characteristics of study population. 
tions than pulmonary vascular resistance (PVR), the more 
conventional indicator of pulmonary vascular disease. 
We have shown that elevation in the TPG is associated 
with increased mortality, but did not explore the relation­
ship of TPG to functional capacity in our previous analy­
ses. 4 While the morphologic cardiac manifestations of 
sickle cell associated cardiomyopathy5·8 and rare left ven­
tricular systolic dysfunction9 have been described, there 
have been no reports using cardiac magnetic resonance 
(CMR) imaging in conjunction with invasive hemody­
namics to understand the relationship of TPG and right 
ventricular (RV) remodeling in patients with SCD. 
Accordingly, we performed a new hypothesis-generat­
ing analysis to assess the relationship of RHC-derived 
TPG and CMR-derived RV remodeling in patients with 
SCD. We also investigated the significance of using a 
TPG threshold and evidence of RV dysfunction to identi­
fy patients with overall poor outcomes. Detailed patient 
enrollment criteria of the Bethesda Sickle Cell Cohort and 







Total bilirubin (mg/dL) 















RV ESVI, ml/m2 
RV EDVI, ml/m' 
RV Mass Index, g/m2 
Left Ventricle 
LVEF, % 
LV ESVI, ml/m' 
LV EDVI, ml/m' 
LV Mass Index, g/m2 
TPG < 12 mmHg TPG <!: 12 mmHg TPG < 12 mmHg TPG <!: 12 mmHg 
n=38 n=46 n=20 n=21 
22 (58%) 24 (52%) 11 (55%) 11 (52%) 
41 ± 14 40 ± 13 44 ± 15 40 ± 15 
33 (87%) 36 (78%) 16 (80%) 17(81%) 
8.1 ± 1.6* 9.3 ± 1.5* 8.1 ± 1.7* 9.6 ± 1.6* 
48 ± 24 47 ± 22 45 ± 28 48 ± 19 
30 ± 20 31 ± 18 25 ± 14 29 ± 12 
3.2 ± 2.2 2.9 ± 2.2 3.0 ± 1.8 2.9 ± 1.8 
0.5 ± 0.4 0.4 (0.3 -0.7) 0.4 ± 0.3 0.5 ± 0.2 
0.7 (0.5-1.0) 1.0 ± 0.9 0.7 (0.6-1.5) 0.95 ± 0.33 
21 (19-26) 37 (30-45)* 21 (19-26) 38 (29-45)* 
9 (5-10) 9 (6-13) 7 (4-10) 9 (6-12) 
13 (11-16) 14 (12-17) 13 (11-17) 13 (12-16) 
5.6 (4.1-6.4) 4.0 (3.3 -5.0)* 6.0 ( 4.9 -6.7) 3.5 (3.0 -4.4) * 
75 (61-92) 56 (47 -71)* 83 (68-99) 54(46-67) * 
14 (10-18) 20 (15-25)* 15 (12 -19) 18 (15-23)* 
76 (58-90) 54 (44-77)* 84 (66-93) 49 (36-61)* 
6.8 (6.0-9.1) 3.1 (2.2 -5.2) * 6.6 (5.5 -10.8) 3.7 (2.0-4.6)* 
121 (95-166) 406 (265-662)* 116 (95-144) 459 (312-694)* 
635 (543-831) 818 (705-946)* 580 (519 -898) 868 (713 -1098)* 
74 (71-76) 69 (65-73)* 74 (69 -76) 69 (66-73)* 
Reference Values (MESA)" 
66 ± 10 53 (41-56) 37 (30-50)* 
27 ± 9 42 (34-54) 57 (43-71)* 
76 ± 15 87 (72 -105) 90 (78 - 106) 
NIA 23 (16-30) 26 (22 -33) 
Reference Values (Maceira et al.)'5 
67 ± 5 58 (52 -60) 55 (50-60) 
26±5 57 (45-73) 43 (37 -59)* 
78 ± 9 138 (108-170) 102 (84-119)* 
69 ± 8 81 (57 -91) 67 (54-78)* 
Average heart rates were comparable between the low vs. high TPG groups (71 ±13 bpm vs 73±14 bpm, P=O. 73). Reference values from the Multi-Ethnic Study of Atherosclerosis 
(MESA) reflect an average of measurements for males and females. Two-tailed ? -values were calculated between those with low vs. high TPG using the Wilcoxon-Mann-Whitney 
U test An asterisk (*) indicates statistical significance (P<O. 00 I ).ALT alanine aminotransferase; AST aspartate aminotransferase; Cl: cardiac index; CVP: central venous pres­
sure; EDVl' end-diastolic volume index; EF ejection fraction; ESVJ: end-systolic volume index; Hb: hemoglobin; LV left ventricular; LVSWJ: left ventricular stroke work index; 
mPAP: mean pulmonary artery pressure; PAWP: pulmonary artery wedge pressure; PVC: pulmonary vascular capacitance (ratio of SV/PP); PVRJ: pulmonary vascular resist­
ance index; RV right ventricular; RVSWJ: right ventricular stroke work index; SVJ: stroke volume index; SV02: mixed venous oxygen saturation; SVR: systemic vascular resist­
ance; TPC: transpulmonary pressure gradient. 






















study procedures have been described.4 Descriptions of 
procedures and image acquisition are available in the 
Online Supplementary Methods. Data from 84 consecutive 
patients with RHC were analyzed; 4 1  patients under­
went CMR within two days of RHC. Patient characteris­
tics are summarized in Table 1. The hemodynamic com­
position of sickle cell patients with normal vs. elevated 
TPG are further described in the Online Supplementary 
Appendix Table S 1.
Univariate analyses showed TPG ;,, 12mmHg and right 
ventricular ejection fraction (RVEF) <32% were signifi­
cant predictors of poor survival (Figure 1). In multivariate 
analysis controlling for age and phenotype, TPG ;,,12 
mmHg and RVEF <32% remained independently predic­
tive of increased mortality (adjusted hazard ratio [HR] 
5.47, 95% CI 1.13-26.42, P=0.035 and adjusted HR 5.11, 
95% CI 1.13-23.13, P=0.034, respectively). A TPG 
A 
10 0 
LETTERS TO THE EDITOR 
;,,12mmHg identified sickle cell patients with a lower 
than expected cardiac index (P<0.05) (Table 1) and hemo­
dynamics consistent with ventricular interdependence. 
Patients with TPG d2mmHg had a higher prevalence of 
late gadolinium enhancement (LGE) at the right ventricu­
lar insertion points (RVIP) (P= 0.03 0, Figure 2A) and 
abnormal CMR markers of ventricular remodeling, 
including increased ventricular mass index (P=0.016, 
Figure 2B), increased septa-marginal trabeculae (SMT) 
mass index (P=0.002), and decreased end-diastolic septal­
to-LV free wall curvature ratio (P=0.013). LY eccentricity 
index at end-systole was greater in those with high TPG 
(P=0.026), indicative of elliptical distortion (Figure 2C). 
A significant negative correlation was observed 
between CMR-derived RVEF and TPG (Spearman 
r=- 0.54, P<0.001). RV dysfunction was also associated 
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Figure 1. Hemodynamic and CMR predictors of mor­
tality in patients with sickle cell disease. (A) Kaplan­
Meier survival curve illustrates decreased survival 
among sickle cell patients with CMR-derived RVEF 
<32% (n=41). (B) Using a combination of transpul­
monary gradient (TPG) and pulmonary artery wedge 
pressure (PAWP) (n=84) as predictors, Kaplan-Meier 
survival curves illustrate highest mortality in patients 
with TPG 2'12mmHg and PAWP 2'15mmHg (52% [14 
out of a total of 27 deaths]. P=0.001) versus the 
three remaining groups. Using PAWP 2'15mmHg vs. 
PAWP <15mmHg alone to dichotomize mortality 
showed no statistical significance (59% [16 out of 27 
deaths] vs. 41% [11 out of 27 deaths]. P=0.121). All 
subjects were censored at 7.9 years. Median follow­






















LETTERS TO THE EDITOR 
Figure 2. CMR markers of right ventricular remodeling in sickle cell patients with an elevated transpulmonary gradient (TPG). Compared 
to sickle cell patients with a transpulmonary gradient (TPG) <12mmHg, those with TPG 2'.12mmHg have (A) higher frequency of late gadolin­
ium enhancement at the right ventricular insertion point (arrows), (B) higher ventricular mass index, (RV:LV ratio) and (C) higher eccentricity 
index indicative of elliptical distortion at end-systole consistent with ventricular interdependence. RV: right ventricle; LV: left ventricle. 
tional classification III/N (P=0.038), and shorter 6-
minute walk distance (6-MWD) (P=0.043). Although the 
sample size limited our ability to directly compare imag­
ing and hemodynamic data in different combinations of 
those with and without elevated TPG and PH, we did 
observe that those with mPAP .e25mmHg and high TPG 
also had a lower RVEF (6 out of 18 with RVEF <32%) and 
higher mortality (10 out of 18 died). We noted that 
patients with high TPG were limited in their exercise 
capacity during the 6-MWD. Thirty-three percent of 
patients in the high TPG group experienced NYHA class 
III-N symptoms of dyspnea, angina, and syncope com­
pared to 18% in the low TPG group.
Lastly, a trend for increased mortality was observed in 
those with an LV EDVl ,;l 15mL/m2 (HR 3.0, P=0.091), RV 
EDVl .e84mL/m2 (HR 2.67, P=0.14), or RV mass index 
.e34g/m2 (HR 2.93, P=0.108). An LV EDVl ,;l15mL/m2 
was associated with increased symptom severity 
(P=0.047) and decreased 6-MWD (P=0.003). Multivariate 
analyses of continuous variables, controlling for age and 
phenotype, showed significant association between LV 
EDVl, ventricular mass index, and SMT mass index with 
NYHA III/N classification and a 6-MWD ,;400 meters 
(P<0.05). 
In this hypothesis-generating analysis, we demonstrat­
ed CMR evidence of RV remodeling in those with elevat­
ed TPG. We found that a CMR-derived RVEF <32% was 
associated with decreased survival and higher NYHA 
classification. A TPG d2mmHg effectively categorizes 
adults with SCD by symptom severity, functional capac­
ity, mortality, and RV function. 
Patients with SCD and elevated PA pressure often 
demonstrate features of either pre- or post-capillary PH, 
and sometimes both simultaneously, 10 but with a distinc­
tive hemodynamic profile: typically borderline elevation 
in mPAP and PVR along with a higher CO when com­
pared to their idiopathic PAH counterpart.10'11 Despite the 
borderline elevation in mPAP and PVR, patients with 
SCD have similar mortality rates to those with PAH. It 
is accepted that normal resting mPAP is 8-20mmHg; 
whereas a mPAP .e25mmHg by RHC is considered to be 
the threshold for diagnosis of PH. A mPAP between 21-
24mmHg is of unclear clinical significance. However, 
recent data12 suggest that in those with borderline mPAP, 
an elevated TPG was associated with poor survival. 
Vachiery et al. 13 recently called for a change in terminolo­
gy when describing the contribution of a pre-capillary 
component to post-capillary PH, arguing that mechanical 
components of increased PAWP could trigger pulmonary 
vasoconstriction and associated changes leading to pul­
monary vascular disease, increased RV afterload, and, 
potentially, RV failure. While not a primary aim in our 
analysis, we found that TPG performed similarly to the 
diastolic pulmonary vascular pressure gradient (DPG), a 
marker of increasing interest. We observed that TPG and 
DPG are highly correlated with Pearson's correlation 
r=0.94, P<0.0001. In our modest cohort of SCD patients, 
TPG and DPG performed very similarly in predicting 
mortality (AUC of 0.73 [95% CI 0.61-0.86] for TPG vs. 
0.74 [95% CI 0.61-0.87] for DPG, P=0.68) (Online 
Supplementary Discussion). Herein, rather than classifying 
sickle cell patients as having pre- or post-capillary PH or 
no PH, we classified patients as having a high vs. low 
TPG. This categorization allowed identification of sickle 
cell patients with lower cardiac index (Cl) despite normal 
LVEF and those with poor functional capacity. Previous 
categorization by our group using mPAP .e25mmHg was 
unable to identify those with lower Cl.4 
To our knowledge, no previous report has presented 
CMR evidence of RV remodeling in relation to pul­
monary hemodynamics, functional capacity and progno­
sis in SCD. Several groups have used CMR in small 
patient populations with SCD and/or thalassemia to 
describe RV and LV function,7·8 myocardial perfusion, 
myocardial fibrosis,8 and myocardial iron content.6 Sickle 
cell associated cardiomyopathy was described as 
4-chamber dilation with some having myocardial fibro­
sis, and rarely myocardial iron overload, but no correla­
tive hemodynamics or prognostic data were reported.
We also observed a 4-chamber dilation. However, in 
patients with high TPG, the indexed LV volumes and 
mass were lower while the indexed RV volumes and 
mass were higher with corresponding lower RVEF. Our 
findings suggest that in patients with SCD and high TPG, 
the left heart chamber is typically under-filled and CMR 
findings correlate with RHC findings of higher RVSWI, 
lower LVSWI, and lower LV cardiac index despite normal 
LVEF. Along with RV systolic dysfunction, we observed a 
higher prevalence of LGE at the RVlP in the high TPG 
group, consistent with prior publications.7•8 
Our study has several limitations. Although 84 patients 
underwent RHC, only 41 of our patients had both RHC 
and CMR, which is relatively modest, but remains the 
only published cohort of patients to have both hemody­
namic and CMR studies. Due to the small sample size, 
our findings should be interpreted as hypothesis-generat-






















ing rather than definitive conclusions. Further, the sam­
ple size limitation may have increased type II errors and 
therefore, our study was only able to detect large differ­
ences. Because our subjects were grouped according to 
TPG rather than by non-PH vs. PH based on conventional 
definitions of PH, our preliminary findings should be 
interpreted in the context of those having elevated TPG 
vs. normal TPG rather than those with PH vs. without 
PH. Additionally, our grouping based on TPG also intro­
duced a degree of hemodynamic heterogeneity into our 
study population when one views the population from 
the conventional definition of PH vs. no PH. Despite the 
limitations outlined, we were able to demonstrate statis­
tical difference in many novel CMR markers indicative of 
RV remodeling. 
We noted higher hemoglobin in the high TPG group, 
but the reasons for this may be complex. The higher 
untransfused hematocrit in SCD can contribute to higher 
whole blood viscosity, which may in turn contribute to 
the pressure gradient across the pulmonary circulation. 
PH in the sickle cell population has been associated with 
higher hemolytic rate and lower hemoglobin. As a result, 
clinically symptomatic patients are also more prone to 
having chronic red cell transfusion therapy prior to RHC 
and CMR, potentially elevating their hemoglobin and 
hematocrit at the time of evaluation. These possibilities 
warrant future investigation. 
Our preliminary findings suggest that RV function and 
morphology may have prognostic implications in 
patients with SCD. While TPG may not help to pinpoint 
the specific pathophysiology of PH in SCD, TPG may 
reflect a composite of complex hemodynamic factors 
affecting RV function, and therefore poor outcomes were 
observed in SCD patients with high TPG. Rather than 
using a single measurement or predictor to assess out­
comes in this complex population, perhaps the role of RV 
adaptation to afterload along with other hemodynamic 
variables, including the TPG, merit further investigation 
in a larger cohort to help guide prognosis in patients with 
SCD. 
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